Textbook of Personalized Medicine - Second Edition [2015]

183 can use biomarkers to identify the bacterial population of the individual. Physicians can then manipulate the population of ...

184 do it and when to do it. The marks, which are not part of the DNA itself, can be passed on from cell to cell as cells divide ...

185 explored in this way including the detection of suitable target molecules, without detailed a priori knowledge of specifi c ...

186 fl exible when certain nanoscale particles are put to work as tags or labels. Nanoparticles are the most versatile material ...

187 the therapeutics-effectors (e.g. channels and receptors) interactions and their cell and tissue responses. A multidimensiona ...

K.K. Jain, Textbook of Personalized Medicine, DOI 10.1007/978-1-4939-2553-7_9, 189 © Springer Science+Business Media New York 20 ...

190 recombinant proteins in combination with diagnostic tests to limit their use to patients where they are least likely to indu ...

191 cells is part of ex vivo gene therapy. The cells may be introduced by various routes into the body and selectively implanted ...

192 Role of Stem Cells Derived from Unfertilized Embryos Using unfertilized human oocytes as a source for stem cell is less cont ...

193 Use of Stem Cells for Drug Testing With the ability to isolate, expand and study mesenchymal stem cells (MSCs) in vitro, ind ...

194 immunomodulation. HSCs, genetically engineered with tumor-specifi c receptors, have been transplanted into mice injected wit ...

195 Synthetic short segments of DNA or RNA are referred to as oligonucleotides. The literal meaning of this word is a polymer ma ...

196 to the tumor suppressor gene p53, which frequently shows LOH in cancer cells (Mook et al. 2009 ). Thus RNAi may play an impo ...

197 References Dhiman N, Ovsyannikova IG, Vierkant RA, et al. Associations between SNPs in toll-like receptors and related intra ...

K.K. Jain, Textbook of Personalized Medicine, DOI 10.1007/978-1-4939-2553-7_10, 199 © Springer Science+Business Media New York 2 ...

200 (Gerlinger et al. 2012 ). Multiple samples from each patient’s primary and metastatic tumor sites were obtained in a study o ...

201 are reviewed elsewhere (Korsunsky et al. 2014 ). The authors have pointed out the need for ways to simulate and analyze canc ...

202 clinical oncology practice through companion molecular diagnostics for personal- ized therapy, the increasing amount of glob ...

203 A Universal NGS-Based Oncology Test System In partnership with pharma companies Illumina is developing a universal NGS- base ...

204 show how actively they are being used. The data are analyzed by advanced statistical techniques to accurately detect deletio ...